Lynparza plus abi/pred approved in Japan for treatment of prostate cancer
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
Centre aims to train surgeons and other healthcare professionals from India and Southeast Asia in robotic-assisted surgery
India will account for about 18% of the Asia-Pacific (APAC) MRI systems market in 2023
The company has entered into a three-year Deferred Prosecution Agreement
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Mizoram appoints Youth for Action as the Interfacing Agency for implementing the ABDM Microsite in Aizawl
Rs. 64000 crores are being invested across the 750 districts of India, to create a more resilient healthcare system in the country
Eris Lifesciences enters into term loan agreement with Citi Bank
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
Subscribe To Our Newsletter & Stay Updated